AC Immune to Receive Research Grant from Goradia Family for Development of ACI-7104 in Parkinson’s Disease
AC Immune to Receive Research Grant from Goradia Family for Development of ACI-7104 in Parkinson’s Disease Grant supports extension of...
Brain
AltaPointe Health Child Psychiatrist Explains New Surgeon General Advisory About Children’s Screen Time
MOBILE, Ala., June 10, 2026 /PRNewswire/ -- A new advisory from the U.S. Surgeon General is encouraging parents to take...
M2M Healthcare Market Size to Reach USD 28.77 Billion by 2031 Driven by Connected Healthcare and Remote Monitoring Adoption | Valuates Reports
BANGALORE, India, June 10, 2026 /PRNewswire/ -- What is the Market Size of M2M Healthcare?According to Valuates Reports, The global...
M2M Healthcare Market Size to Reach USD 28.77 Billion by 2031 Driven by Connected Healthcare and Remote Monitoring Adoption | Valuates Reports
BANGALORE, India, June 10, 2026 /PRNewswire/ -- What is the Market Size of M2M Healthcare?According to Valuates Reports, The global...
Digital Medical Partnerships Market Size to Reach USD 3.76 Billion by 2031 Driven by Healthcare Digital Transformation and Connected Care Growth | Valuates Reports
BANGALORE, India, June 10, 2026 /PRNewswire/ -- What is the Market Size of Digital Medical Partnerships?According to Valuates Reports, The...
Digital Medical Partnerships Market Size to Reach USD 3.76 Billion by 2031 Driven by Healthcare Digital Transformation and Connected Care Growth | Valuates Reports
BANGALORE, India, June 10, 2026 /PRNewswire/ -- What is the Market Size of Digital Medical Partnerships?According to Valuates Reports, The...
Early Brain Aneurysm Foundation Funding Helps Drive Breakthrough in Understanding How Brain Aneurysms Form and Weaken
New UCSF study, published today in Nature Neuroscience, identifies a destructive cellular process that weakens artery walls and could help...
Early Brain Aneurysm Foundation Funding Helps Drive Breakthrough in Understanding How Brain Aneurysms Form and Weaken
New UCSF study, published today in Nature Neuroscience, identifies a destructive cellular process that weakens artery walls and could help...
CervoMed Announces Private Placement Financing and Plan to Focus on Strategic Partnering to Advance Neflamapimod into Phase 3 for Dementia with Lewy Bodies
Additional funding will extend anticipated runway into second quarter of 2027 Strategic priority is to establish a partnership to advance...
CONNECTA Therapeutics Initiates Phase IIa Clinical Trial of CTH120, a First-in-Class Neuroplasticity Modulator, in Fragile X Syndrome
Builds on positive Phase I safety data and represents a key value-inflection milestone for the CompanyAdvances a potentially disease-modifying approach...
AI IS A FORCE MULTIPLIER FOR NEUROPATHOLOGY AT UC DAVIS
DEMENTIA RESEARCH IS SUPPORTED BY A GIFT FROM SUSAN AND CHARLES BERGHOFF FOUNDATIONMORGAN HILL, Calif., June 9, 2026 /PRNewswire/ --...
In HelloNation, ADHD Coaching Expert Germaine Swanson Explains What to Expect From ADHD Coaching
The article outlines how ADHD coaching supports executive function, daily routines, accountability, and long-term personal growth.TAYLOR, Mich., June 9, 2026...
Verge Labs and Tenacia Biotechnology Partner to Advance Tenacia’s CNS Pipeline Using Human Data
First partnership announced under Verge Labs' platform-first model; Tenacia will apply Verge's AI platform and proprietary multimodal human tissue data...
Kids Can Earn a “PhD in Poop” at The Poop Museum’s New Science Summer Camp!
BOSTON, June 9, 2026 /PRNewswire/ -- The Poop Museum, the popular science education program that has taught 50,000 curious humans...
BrainsWay Presents First SWIFT™ Accelerated Deep TMS 12-Month Durability Data at Clinical TMS Society Annual Meeting
Preliminary Data Analysis Reveals Over 80% Remission Rate One Year after Accelerated Deep TMS Treatment, with Decline in Severe Functional...
TG Therapeutics Announces Positive Topline Phase 1 Data for Subcutaneous BRIUMVI in Patients with Myasthenia Gravis and Initiation of Potential Registration Directed Randomized Phase 2 Trial
82% of subjects achieved an MCID in their MG-ADL with a mean >4 point improvement in MG-ADL observed in Phase...
Alterity Therapeutics Achieves Alignment with U.S. FDA on Pivotal Phase 3 Program for ATH434 in Multiple System Atrophy
– Successful End-of-Phase 2 meeting with FDA agreeing on key elements of the proposed Phase 3 design, including study population,...
BPGbio Appoints Renowned Neuroscientist Eric J. Nestler, M.D., Ph.D., as Chair of Scientific Advisory Board
BPGbio Appoints Renowned Neuroscientist Eric J. Nestler, M.D., Ph.D., as Chair of Scientific Advisory Board Dr. Nestler, world-renowned neuroscientist, Dean...
Life Biosciences Announces First Patient Dosed in Phase 1 Trial of ER‑100 for Optic Neuropathies
Lead epigenetic restoration therapy enters the clinic for glaucoma and NAION, targeting a root cause of age-related vision loss BOSTON,...
As the Ebola Emergency Outbreak Grows Rapidly, NanoViricides Has Proposed a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment – with Superior Oral Administration and Escape Resistance Features Over Antibodies
SHELTON, CT / ACCESS Newswire / June 8, 2026 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader...